.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Find suppliers and generic API sources
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Cerilliant
Teva
US Army
Chubb
Citi
McKinsey
US Department of Justice
AstraZeneca

Generated: July 26, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Piperidine derivatives
Abstract:The present invention relates to substantially pure piperidine derivative compounds of the formulae: ##STR1## wherein R.sub.1 is hydrogen or hydroxy; R.sub.2 is hydrogen; or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2 ; R.sub.3 is --COOH or --COOR.sub.4 ; R.sub.4 has 1 to 6 carbon atoms; A, B, and D are the substituents of their respective rings each of which may be different or the same and are hydrogen, halogens, alkyl, hydroxy, alkoxy, or other substituents. A process of preparing such piperidine derivative compounds in substantially pure form is also disclosed.
Inventor(s): D'Ambra; Thomas E. (Wynantskill, NY)
Assignee: Albany Molecular Research, Inc. (Albany, NY)
Application Number:08/456,273
Patent Claims: 1. A substantially pure piperdine derivative compound of the formulae: ##STR42## wherein R.sub.1 is hydrogen or hydroxy;

R.sub.2 is hydrogen;

or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2 ;

R.sub.3 is --COOH or --COOR.sub.4 ;

R.sub.4 is an alkyl with 1 to 6 carbon atoms;

A, B, and D can be one or more different substituents of their rings and are individually hydrogen, halogens, alkyl, hydroxy, or alkoxy,

or a salt thereof.

2. A substantially pure piperidine derivative compound according to claim 1, wherein the compound has the formula: ##STR43##

3. A substantially pure piperidine derivative compound according to claim 1, wherein the compound has the formula: ##STR44##

4. A substantially pure piperidine derivative compound according to claim 1, wherein the compound has the formula: ##STR45##

5. A substantially pure piperidine derivative compound according to claim 4, wherein the compound has the formula: ##STR46##

6. A substantially pure piperidine derivative compound according to claim 1, wherein the compound has the formula: ##STR47##

7. A substantially pure piperidine derivative compound according to claim 6, wherein the compound has the formula: ##STR48##

8. A pharmaceutical composition comprising:

a pharmaceutical carrier and

the substantially pure piperidine derivative compound according to claim 1.

9. A pharmaceutical composition according to claim 8, wherein said substantially pure piperidine derivative compound is present in an effective antiallergic amount.

10. A pharmaceutical composition according to claim 8, wherein said composition consists essentially of said substantially pure piperidine derivative compound.

11. A method of treating allergic reactions in a patient comprising:

administering to the patient said pharmaceutical composition according to claim 8 in an effective amount.

12. A piperidine derivative compound produced by a process comprising:

providing a substantially pure regioisomer of the following formula: ##STR49## wherein R.sub.3 is --COOH or --COOR.sub.4 ;

R.sub.4 has 1 to 6 carbon atoms;

A is the substituents of its ring, each of which may be different or the same, and are selected from the group consisting of hydrogen, halogens, alkyl, hydroxy, or alkoxy, and

converting the substantially pure regioisomer with a piperidine compound of the formula: ##STR50## wherein R.sub.1 is hydrogen or hydroxy;

R.sub.2 is hydrogen;

or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2 ;

B and D are the substituents of their rings, each of which may be different or the same, and are selected from the group consisting of hydrogen, halogens, alkyl, hydroxy, or alkoxy

under conditions effective to form a compound of the formula: ##STR51##

13. A piperidine derivative compound according to claim 12, wherein said providing comprises:

acylating a starting compound of the formula: ##STR52## wherein R.sub.5 is --OR.sub.6, --N(R.sub.6).sub.2, and --SR.sub.6, and

R.sub.6 is an alkyl with 1 to 6 carbons,

with a compound of the formula: ##STR53## wherein X is a halogen,

under conditions effective to produce a first mixture of regioisomers of the formula: ##STR54## hydrolyzing the first mixture of regioisomers under conditions effective to form a second mixture of a regioisomers of the formula: ##STR55## recovering from the second mixture of regioisomers the substantially pure regioisomer of the formula: ##STR56##

14. A piperidine derivative compound according to claim 12, wherein said providing comprises:

acylating a starting compound of the formula: ##STR57## with a compound of the formula: ##STR58## wherein X.sub.1 is a halogen, trialkyl tin, triflate, or substituents useful in organometallic coupling reactions

under conditions effective to produce the substantially pure regioisomer of the formula: ##STR59##

15. A piperidine derivative compound according to claim 12, wherein said providing comprises:

acylating a starting compound of the formula: ##STR60## wherein R.sub.5 is --OR.sub.6, --N(R.sub.6).sub.2, and --SR.sub.6, and

R.sub.6 is an alkyl with 1 to 6 carbon atoms

with a compound of the formula: ##STR61## under conditions effective to produce a first mixture of regioisomers of the formula: ##STR62## hydrolyzing the first mixture of regioisomers under conditions effective to form a second mixture of regioisomers of the formula: ##STR63## recovering from the second mixture of regioisomers the substantially pure regioisomer of the following formula: ##STR64##

16. A piperidine compound according to claim 12, wherein said converting comprises:

halogenating the substantially pure regioisomer of the following formula: ##STR65## under conditions effective to form a first intermediate compound of the formula: ##STR66## wherein X is a halogen and

reacting the first intermediate compound with a piperidine compound of the formula: ##STR67## under conditions effective to form the piperidine derivative of the following formula: ##STR68##

17. A piperidine compound according to claim 12, wherein said converting comprises:

reacting the substantially pure regioisomer of the following formula: ##STR69## with a piperidine compound of the formula: ##STR70## under conditions effective to form the piperidine derivative of the formula: ##STR71##
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Farmers Insurance
QuintilesIMS
AstraZeneca
Chinese Patent Office
Julphar
Covington
Boehringer Ingelheim
Cipla
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot